Literature DB >> 17502555

Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.

C G Ballard1, K A Chalmers, C Todd, I G McKeith, J T O'Brien, G Wilcock, S Love, E K Perry.   

Abstract

Cholinesterase inhibitors (ChEIs) are effective symptomatic treatments in dementia with Lewy bodies (DLB), although effects on pathologic mechanisms are unknown. In the first human autopsy study examining the impact of ChEI treatment on brain pathology, we compared treated patients with DLB with matched untreated patients for cortical beta-amyloid (Abeta) and tau pathologies. Treated patients with DLB had significantly less parenchymal Abeta deposition, which is relevant to disease management and treatment of dementia patients using ChEI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502555     DOI: 10.1212/01.wnl.0000261920.03297.64

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  19 in total

Review 1.  The role of phytochemicals in the treatment and prevention of dementia.

Authors:  Melanie-Jayne R Howes; Elaine Perry
Journal:  Drugs Aging       Date:  2011-06-01       Impact factor: 3.923

2.  Dementia with lewy bodies: diagnosis and management for primary care providers.

Authors:  Melanie Zupancic; Aman Mahajan; Kamna Handa
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model.

Authors:  Loqman A Mohamed; Jeffrey N Keller; Amal Kaddoumi
Journal:  Biochim Biophys Acta       Date:  2016-01-15

4.  Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.

Authors:  Victor Bloniecki; Dag Aarsland; Kaj Blennow; Jeffrey Cummings; Farshad Falahati; Bengt Winblad; Yvonne Freund-Levi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 5.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

6.  Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.

Authors:  D Aarsland; C Ballard; A Rongve; M Broadstock; P Svenningsson
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

7.  Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats.

Authors:  Loqman A Mohamed; Hisham Qosa; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2015-03-30       Impact factor: 4.418

8.  Effect of Trigonella foenum-graecum Linn. seeds methanol extract on learning and memory.

Authors:  Tahira Assad; Rafeeq Alam Khan; Muhammad Ali Rajput
Journal:  Metab Brain Dis       Date:  2018-04-21       Impact factor: 3.584

Review 9.  Alzheimer's disease as homeostatic responses to age-related myelin breakdown.

Authors:  George Bartzokis
Journal:  Neurobiol Aging       Date:  2009-09-22       Impact factor: 4.673

Review 10.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.